We encourage you to republish this article online and in print, it’s free under our creative commons attribution license, but please follow some simple guidelines:
  1. You have to credit our authors.
  2. You have to credit SciDev.Net — where possible include our logo with a link back to the original article.
  3. You can simply run the first few lines of the article and then add: “Read the full article on SciDev.Net” containing a link back to the original article.
  4. If you want to also take images published in this story you will need to confirm with the original source if you're licensed to use them.
  5. The easiest way to get the article on your site is to embed the code below.
For more information view our media page and republishing guidelines.

The full article is available here as HTML.

Press Ctrl-C to copy

In a bid to boost its economy ever higher, China is investing heavily in technology — nanotechnology and biotechnology in particular. But transforming research into profits is tricky, particularly in a post-dotcom climate of cautious investment.

In this article, James C. Hsiao and Kenneth Fong, chairmen of US companies Inframat and Kenson Ventures respectively, examine how three successful technology companies do it. They found that a good intellectual-property portfolio, effective management team and consumer demand — coupled with funding strong on government contracts and corporate partnerships — work best. 

The authors note that China's open-door policy promises plenty of Western involvement. And, they firmly believe, a future as world leader in nanotechnology and biotechnology.

Link to full article in Nature 

Reference: Nature 428, 218 (2004)

Related topics